Sun Pharma Founder Says “Debt-Averse, Not Risk-Averse” After $12 billion Organon Buy
Organon will boost Sun Pharma’s global presence by 40 countries.
Welcome to India Edition, Bloomberg’s daily dive into what’s moving the worlds of business, markets and politics in this dynamic, fast-paced economy. I’m Menaka Doshi . If you didn’t receive this directly in your inbox, you can subscribe here , and share feedback with us here .
Today, I look at Sun Pharma’s audacious bet to become one of the world’s 25 largest drugmakers, and my colleague Sudhi Ranjan Sen analyzes the learnings for India from the war in Iran.